ReviewMedical gas research2027
Gas signaling molecule: a new research focus in the treatment of erectile dysfunction.
Review in Medical gas research, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gas signaling molecules, including nitric oxide, carbon monoxide, and hydrogen sulfide, have recently gained attention in erectile dysfunction treatment research because of their roles in regulating blood vessel function, reducing oxidative stress, and protecting nerves and other cells. This article reviews how nitric oxide, carbon monoxide, and hydrogen sulfide are involved in the development of erectile dysfunction and their potential as treatments. The review focuses on how these gases improve blood vessel function, relax smooth muscles, repair nerve function, and reduce tissue scarring. Current research shows that methods of gas delivery, especially those using nanocarriers or prodrugs, greatly increase how well these gases are absorbed and where they act in the body. Early animal studies and initial clinical trials support the effectiveness of these gasotransmitters in treating various causes of erectile dysfunction, including diabetes, aging, and nerve damage. Although challenges remain in controlling the speed of delivery, determining the appropriate dosage, and tailoring treatment to individual patients, there is reason for optimism. The development of responsive delivery systems, combinations of multiple gases, and additional therapies for difficult cases suggests that gas signaling molecules could transform erectile dysfunction treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.